EMA: European Medicines Agency confirms positive benefit-risk balance of somatropin-containing medicines

Finalising its review of somatropin-containing medicines, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) confirms that the benefit-risk balance of these medicines remains positive. However, the CHMP wished to remind prescribers to strictly follow the approved indications and doses and to carefully consider the warnings and precautions for somatropin-containing medicines.